论文部分内容阅读
一、药品降价竞销原因分析近年来,对医药商品价格颇多异议:一方面降价竞销,回扣愈扩愈大,另一方面药价趋高,药费昂贵,病患者不甚负担。有关调查表明,这种价格的反差现象在实行国家定价的化学药品(包括中成药,下同)中尤为突出,已严重影响企业产品结构的合理调整和药品的质量信誉。由于原材料、能源涨价,劳动力价格提高,各种费用上升,技术改造步伐加快等因素使成本趋高,药价趋涨,这是正常的,但愈演愈烈的压价竞销、扩扣让利却使正常提价申辩无力。具有国家定价形式的药品,实际执行低于国家规定的价格。药品价格不到位现象,应引起各有关部门的重视。药品价格不到位现象以其品种多,降幅大,涉及领域广的特点,干扰了正常的医药生产经营和管理。其原因何在呢?
I. Analysis of the causes of drug price reduction competition sales In recent years, there have been many objections to the prices of pharmaceutical products: on the one hand, price cuts have been competed for sales, and the rebates have been increasing. The increase in drug prices has resulted in high drug prices and the burden on patients is not enough. Relevant investigations have shown that this kind of price contrast phenomenon is particularly prominent in the implementation of national pricing of chemical drugs (including proprietary Chinese medicines, the same below), which has seriously affected the rational adjustment of the product structure of the enterprise and the quality reputation of drugs. As raw materials and energy prices rise, the price of labor rises, various costs increase, and the pace of technological transformation accelerates, the cost tends to rise, and drug prices tend to rise. This is normal, but the price of competitive price promotions and discounts has been increased. There is no power to raise price. Drugs with national pricing are actually executed at prices lower than the national regulations. The phenomenon that the prices of drugs are not in place should be brought to the attention of all relevant departments. The phenomenon that the price of medicines is not in place is characterized by a large number of varieties, a large drop, and a wide range of fields, which interferes with normal pharmaceutical production and management. What are the reasons for this?